Skip to content

Withania somnifera ranked highest for quality of life in a breast cancer review

A network meta-analysis favored Withania somnifera for several patient-reported outcomes, but the abstract leaves key details about comparisons and certainty unresolved.

By 100HP editorialAbstract-based explanation checked

Based on the published abstract. The full paper may contain additional methods, results and limitations.

The 30-second takeaway

The analysis ranked Withania somnifera highest for quality of life and several symptom and functioning outcomes. The reported outcomes concern patients' experiences during breast cancer care. Rankings indicate how treatments compared within the analysis; they do not establish a dependable treatment choice, and the authors call for further clinical validation.

Keep in mind

This abstract-based assessment cannot resolve treatment duration, the studies supporting each comparison, safety or risk of bias. Those details matter when interpreting the reported standardized effects and deciding how much confidence to place in the rankings.

THE NUMBERS, WITH CONTEXT

What researchers found

SMD 4.66 (95% CI: 3.47–5.85)

Patient-reported quality of life

Withania somnifera versus standard treatment; assessment timing was not reported. The standardized mean difference expresses the quality-of-life difference in standard-deviation units, with a positive estimate favoring Withania somnifera.

Front Pharmacol, 2025 · Original source ↓

What the rankings mean

The researchers used SUCRA probabilities to rank treatments across outcomes. A high ranking is not the percentage of patients who improved, and it does not describe the absolute size of a patient's improvement.

Scope of the reported outcomes

Fatigue, pain, nausea and physical, role and emotional functioning were also examined. The abstract ranks Withania somnifera favorably across these domains, but does not provide detailed effect estimates for every symptom outcome.

CHECK THE ORIGINAL

The original publication

Systematic review and network meta-analysis of the effects of plant active substance on quality of life in breast cancer patients.

Wang L, Xu X, Guo M et al.
Front Pharmacol · 2025

PubMed ID
41394145
Record checked

AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.